(Q46232500)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19027483%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

title

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19027483%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

main subject

phase III clinical trial

0 references

1 reference

1 reference

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19027483%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Tony Mok

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19027483%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

18

Jean-Yves Douillard

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19027483%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

17

Scott M Lippman

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19027483%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

author name string

Edward S Kim

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19027483%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Vera Hirsh

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19027483%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Mark A Socinski

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19027483%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Radj Gervais

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19027483%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Long-Yun Li

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19027483%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Claire L Watkins

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19027483%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Mark V Sellers

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19027483%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Elizabeth S Lowe

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19027483%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Yan Sun

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19027483%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Mei-Lin Liao

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19027483%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Kell Osterlind

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19027483%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Martin Reck

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19027483%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Alison A Armour

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19027483%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Frances A Shepherd

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19027483%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

language of work or name

English

0 references

publication date

1 November 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19027483%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19027483%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

volume

372

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19027483%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

page(s)

1809-1818

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19027483%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

issue

9652

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19027483%20AND%20SRC:MED&resulttype=core&format=json

Global cancer statistics, 2002

17 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961758-4

7 January 2021

Cancer statistics, 2007

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961758-4

7 January 2021

Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961758-4

7 January 2021

Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961758-4

7 January 2021

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961758-4

7 January 2021

Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961758-4

7 January 2021

Gefitinib--a novel targeted approach to treating cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961758-4

7 January 2021

Erlotinib in previously treated non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961758-4

7 January 2021

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961758-4

7 January 2021

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961758-4

7 January 2021

Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961758-4

7 January 2021

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961758-4

7 January 2021

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961758-4

7 January 2021

Sequential Treatment Assignment with Balancing for Prognostic Factors in the Controlled Clinical Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961758-4

7 January 2021

The Functional Assessment of Cancer Therapy scale: development and validation of the general measure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961758-4

7 January 2021

Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961758-4

7 January 2021

What is a clinically meaningful change on the Functional Assessment of Cancer Therapy-Lung (FACT-L) Questionnaire? Results from Eastern Cooperative Oncology Group (ECOG) Study 5592.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961758-4

7 January 2021

Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961758-4

7 January 2021

Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961758-4

7 January 2021

A sharper Bonferroni procedure for multiple tests of significance

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961758-4

7 January 2021

Design and analysis of non-inferiority mortality trials in oncology.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961758-4

7 January 2021

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961758-4

7 January 2021

Erlotinib in lung cancer - molecular and clinical predictors of outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961758-4

7 January 2021

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961758-4

7 January 2021

Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961758-4

7 January 2021

Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961758-4

7 January 2021

10.1016/S0140-6736(08)61758-4

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19027483%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

1 reference